Societe Generale Downgrades Fresenius Medical Care to Hold - Money Flow Index Print

Brokerage firm Societe Generale Downgrades its rating on Fresenius Medical Care(NYSE:FMS). The shares have been rated Hold. Previously, the analysts had a Buy rating on the counter. The rating by Societe Generale was issued on Aug 13, 2015.

Fresenius Medical Care Corporation (NYSE:FMS): 5 analysts have set the short term price target of Fresenius Medical Care Corporation (NYSE:FMS) at $43.61. The standard deviation of short term price target has been estimated at $5.04, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 50 and $39 respectively. Institutional Investors own 2% of Company shares. During last 3 month period, 1.24% of total institutional ownership has changed in the company shares. The company shares have rallied 19.84% from its 1 Year high price. On Jun 4, 2015, the shares registered one year high at $44.34 and the one year low was seen on Oct 16, 2014. The 50-Day Moving Average price is $42.47 and the 200 Day Moving Average price is recorded at $41.34. Fresenius Medical Care Corporation (NYSE:FMS) : On Monday heightened volatility was witnessed in Fresenius Medical Care Corporation (NYSE:FMS) which led to swings in the share price. The shares opened for trading at $41.4 and hit $41.78 on the upside , eventually ending the session at $41.77, with a gain of 0.51% or 0.21 points. The heightened volatility saw the trading volume jump to 1,101,268 shares. The 52-week high of the share price is $44.34 and the company has a market cap of $26,081 million. The 52-week low of the share price is at $32.4 . Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patient’s peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.